1-(2-Bromoethoxy)-4-nitrobenzene | CAS:13288-06-7

We serve 1-(2-Bromoethoxy)-4-nitrobenzene CAS:13288-06-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-(2-Bromoethoxy)-4-nitrobenzene

Chemical Name:1-(2-Bromoethoxy)-4-nitrobenzene
CAS.NO:13288-06-7
Synonyms:1-(2-Bromoethoxy)-4-nitrobenzene
1-(2-bromoethyloxy)-4-nitro-benzene
4-(2-bromoethoxy)-1-nitrobenzene
1-(4-nitrophenoxy)-2-bromoethane
2-(4-nitrophenoxy)ethyl bromide
1-bromo-2-(4-nitrophenoxy)ethane
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 351.2±22.0 °C at 760 mmHg
Melting Point 62-65ºC
Molecular Formula C8H8BrNO3
Molecular Weight 246.058
Flash Point 166.2±22.3 °C
Vapour Pressure 0.0±0.7 mmHg at 25°C
Index of Refraction 1.584
 
Specification:
Appearance:Off-white to light yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Dofetilide(CAS:115256-11-6).



Contact us for information like 1-(2-Bromoethoxy)-4-nitrobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-bromo-2-(4-nitrophenoxy)ethane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-nitrophenoxy)ethyl bromide Use and application,1-(4-nitrophenoxy)-2-bromoethane technical grade,usp/ep/jp grade.


Related News: Self-isolation involves not going to work, school or into public places.2,4,6-Triisopropylbenzenesulfonyl Azide manufacturer Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.2-Anilino-6-dibutylamino-3-methylfluoran supplier Take penicillin industrial salt and vitamin C as examples. They are the two strategic varieties of chemical raw materials in China, and they are also representatives of severe overcapacity.Isobutyl Chloroformate vendor “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.